Opinion|Videos|March 3, 2025

Key Takeaways on the Evolving Landscape of Pediatric Atopic Dermatitis Treatment

Panelists discuss the current treatment landscape for atopic dermatitis, noting significant advances in biologics and systemic therapies, and share optimism about the future of management, highlighting ongoing research and the potential for more targeted, personalized treatments to improve patient outcomes.

Episodes in this series

3 experts are featured in this series.

EP. 1 Overview of Atopic Dermatitis Pathophysiology and Atopic March in Children

3 experts are featured in this series.

EP. 2 Considerations for Diagnosing Atopic Dermatitis and Assessing Severity

3 experts are featured in this series.

EP. 3 Exploring the Pediatric Patient and Caregiver Journey

3 experts are featured in this series.

EP. 4 Multidisciplinary Approaches to Atopic Dermatitis Management and Referrals

3 experts are featured in this series.

EP. 5 Setting Goals for Pediatric Atopic Dermatitis Treatment

3 experts are featured in this series.

EP. 6 Real-World Challenges to Providing Evidence-Based Care for Atopic Dermatitis

3 experts are featured in this series.

EP. 7 Navigating New Treatment Options for Pediatric Atopic Dermatitis Management

3 experts are featured in this series.

EP. 8 Managing Comorbidities and Mitigating Atopic March in Adolescent and Adult Patients

3 experts are featured in this series.

EP. 9 Expectations for Efficacy and Duration of Response With Systemic Atopic Dermatitis Treatments

3 experts are featured in this series.

EP. 10 Considerations for Switching Systemic Agents in Atopic Dermatitis

3 experts are featured in this series.

EP. 11 Future Directions in the Treatment of Pediatric Atopic Dermatitis

3 experts are featured in this series.

EP. 12 Patient and Caregiver Advice for Navigating Atopic Dermatitis

3 experts are featured in this series.

EP. 13 Key Takeaways on the Evolving Landscape of Pediatric Atopic Dermatitis Treatment

Video content above is prompted by the following:

Please share final thoughts on the current treatment landscape and future of atopic dermatitis management.

Newsletter

Access practical, evidence-based guidance to support better care for our youngest patients. Join our email list for the latest clinical updates.

Related Content

1 expert is featured in this series

Infant Gut Microbiome at Birth: Why Early Colonization Matters

ByKirsi Jarvinen-Seppo, MD, PhD

August 31st 2026

4 Experts are featured in this series

RSV Prevention: Final Reflections and a Vision for the Future

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 20th 2026

4 Experts are featured in this series

RSV Prevention and Vaccine Hesitancy: Building Long-Term Communication

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 20th 2026

4 Experts are featured in this series

RSV Immunization Rates and Vaccine Hesitancy: Practical Strategies for Clinicians

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 13th 2026

4 Experts are featured in this series

RSV and the Challenge of Reinfection: Long-Term Prevention Perspectives

ByFlor M. Munoz, MD, MSc,C. Buddy Creech, MD, MPH,Eric Simões, MD,Tina Q. Tan, MD, FAAP, FIDSA, FPIDS

July 13th 2026

Latest CME

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Progress in Hyperlipidemia Management to Reduce ASCVD Risk: An Illustrated Update

Nihar R. Desai, MD, MPH; Martha Gulati, MD, MS, FACC, FAHA, MASPC, FESC, FSCCT (hon), FRCP Edin

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Is TNF-Like Ligand 1A (TL1A) Inhibition the Answer to Improving Disease Remission in Inflammatory Bowel Disease?

Jordan Axelrad, MD, MPH, FACG, FCCF; Jessica R. Allegretti, MD, MPH; Florian Rieder, MD

Trending on Contemporary Pediatrics

AAP expands RSV immunization recommendations for high-risk children

FDA approves zilganersen (Zanvastro) as first treatment for Alexander disease

HPV vaccination coverage stalls for fourth straight year as rural-urban gap persists, CDC finds

The unharmonious 2026 child and adolescent immunization schedule - addendum

Evidence review supports respiratory virus immunizations for 2026-2027 season